You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Bexsero Mode of Action

Bexsero is an innovative vaccine developed to achieve a robust immune response across age groups against a range of diverse MenB strains. 1

The four immunogenic components of Bexsero are: 2

  • Factor H binding protein (fHbp)
  • Neisserial adhesin A (NadA)
  • Neisseria heparin-binding antigen (NHBA)
  • Porin A (PorA)

Illustration copyrights GlaxoSmithKline

Vaccination with BEXSERO leads to the production of antibodies directed against NHBA, NadA, fHbp, and PorA. 2

  • NHBA binds heparin, which may promote bacterial survival in the blood 3 
  • NadA promotes adherence to and invasion of human epithelial cells 49
  • fHbp binds factor H, which enables bacterial survival in the blood 56
  • PorA is the major target for strain-specific bactericidal response elicited by the MeNZB* vaccine 7

This multiple-antigen approach in BEXSERO may provide synergistic killing, improve strain coverage, and insure against mutations of individual target proteins 8

* MeNZB was developed by Chiron Vaccines in association with the Norwegian Institute of Public Health7

Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health

http://www.phs.moh.gov.cy/web/guest/drug-search

References:

  1. Bai X et al. Expert Opin Biol Ther 2011;11(7):969–985.
  2.  BEXSERO Summary of Product Characteristics
  3.  Serruto D, et al. Proc Natl Acad Sci U S A. 2010;107(8):3770–3775
  4.  Comanducci M, et al. J Exp Med. 2002;195(11):1445–1454
  5.  Madico G, et al. J Immunol. 2006;177(1):501–510
  6.  Schneider MC, et al. Nature. 2009;458(7240):890–893
  7.  Martin DR, et al. Clin Vaccine Immunol. 2006;13(4):486–491
  8.  Vesikari T, et al. Lancet. 2013;381(9869):825–835
  9. Cappecchi et al. Molecular Microbiology 2005;55(3) :687-698

Prescription Only Medicine.
Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health http://www.phs.moh.gov.cy/web/guest/drug-search

Trade marks are owned by or licensed to the GSK group of companies.
© 2020 GSK group of companies or its licensor.